As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered…
Revealing highly active specialties in sciences and social sciences LONDON, Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a…
Revealing highly active specialties in sciences and social sciences LONDON, Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a…
Revealing highly active specialties in sciences and social sciences LONDON, Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a…
Revealing highly active specialties in sciences and social sciences LONDON, Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a…
Accelerating your Transformational Growth Journey: FrostAI's elevated user experience acts as your company's Growth Partner LONDON, Nov. 14, 2024 /PRNewswire/…